Product Description
Mechanisms of Action: ADRB2 Agonist,PDE Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: India | Ireland | Italy | Pakistan | Portugal | Russia
Approved Indications: None
Known Adverse Events: None
Company: MEDA Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Asthma, Exercise-Induced|Asthma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
AERIA | P2 |
Completed |
Asthma |
2008-10-30 |
|
AERIA | P2 |
Completed |
Asthma, Exercise-Induced |
2008-10-01 |
35% |
2006-7041-83/hah | N/A |
Withdrawn |
Nose Cancer |
None |